Hepatosplenic T-cell lymphoma and inflammatory bowel disease (Q37814566)

23 August 2017

1 reference

title

Hepatosplenic T-cell lymphoma and inflammatory bowel disease (English)

1 reference

inflammatory bowel diseases

23 August 2017

0 references

inflammation

0 references

hepatosplenic T-cell lymphoma

1 reference

Anne Thai

1

1 reference

PubMed ID

21122554

23 August 2017

Thomas Prindiville

series ordinal

2

1 reference

PubMed ID

21122554

23 August 2017

language of work or name

1 reference

25 June 2010

1 reference

Journal of Crohn's and Colitis

23 August 2017

1 reference

23 August 2017

4

1 reference

23 August 2017

511-522

1 reference

23 August 2017

5

1 reference

The incidence of lymphoid and myeloid malignancies among hospitalized Crohn's disease patients

23 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Hepatosplenic T cell lymphoma. A review on 45 cases since the first report describing the disease as a distinct lymphoma entity in 1990.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Hepatosplenic alphabeta T-cell lymphomas: a report of 14 cases and comparison with hepatosplenic gammadelta T-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Hepatosplenic gammadelta T-cell lymphoma: relation to Epstein-Barr virus and activated cytotoxic molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Hepatosplenic and other gammadelta T-cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Hepatosplenic T-cell lymphoma of alphabeta lineage in a 16-year-old boy presenting with hemolytic anemia and thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Gamma/delta T cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Hepatosplenic gamma/delta T-cell lymphoma with isochromosome 7q, translocation t(7;21), and tetrasomy 8 in a 9-year-old girl

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Hepatosplenic gammadelta T-cell lymphoma following seven malaria infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Hepatosplenic T-gammadelta lymphoma in a patient with Crohn's disease treated with azathioprine

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Development of hepatosplenic gammadelta T-cell lymphoma with pancytopenia during early pregnancy: a case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Hepatosplenic gammadelta T-cell lymphoma with ring chromosome 7, an isochromosome 7q equivalent clonal chromosomal aberration

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Gamma-delta hepatosplenic T-cell lymphoma. Description of a case with immunophenotypic and molecular follow-up successfully treated with chemotherapy alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Allogeneic bone marrow transplantation for chemotherapy-refractory hepatosplenic gammadelta T-cell lymphoma: case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Hepatosplenic gammadelta T-cell lymphoma successfully treated with a combination of alemtuzumab and cladribine

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Progressive multifocal leukoencephalopathy in a patient with hepatosplenic T cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Hepato-splenic lymphoma: a rare entity mimicking acute hepatitis: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Long-term remission in a patient with hepatosplenic gammadelta T cell lymphoma treated with bortezomib and high-dose CHOP-like chemotherapy followed by autologous peripheral stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Pituitary gland involvement by a gamma delta hepatosplenic lymphoma, a mimicker of pituitary adenoma: report of a rare case

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Hepatosplenic alphabeta T-cell lymphoma with myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Hepatosplenic gammadelta T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

In vitro and in vivo effects of 2'-deoxycoformycin (Pentostatin) on tumour cells from human gammadelta+ T-cell malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

2'-Deoxycoformycin for hepatosplenic gammadelta T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Hepatosplenic gammadelta T-cell lymphoma: complete response induced by treatment with pentostatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Long-term survival with allogeneic stem cell transplant and donor lymphocyte infusion following salvage therapy with anti-CD52 monoclonal antibody (Campath) in a patient with alpha/beta hepatosplenic T-cell non-Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Hemophagocytic syndrome and hepatosplenic gammadelta T-cell lymphoma with isochromosome 7q and 8 trisomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Fulminant liver failure induced by hepatosplenic alphabeta T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Hepatosplenic T cell lymphoma with no expression of cytotoxic molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Hepatosplenic gammadelta-T-cell lymphoma with leukemic course after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Hepatosplenic gammadelta T-cell lymphoma presenting with immune-mediated thrombocytopenia and hemolytic anemia (Evans' syndrome).

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Fluorescence in situ hybridization study of chromosome 7 aberrations in hepatosplenic T-cell lymphoma: isochromosome 7q as a common abnormality accumulating in forms with features of cytologic progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Hepatosplenic gamma/delta T-cell lymphoma in immunocompromised patients. Report of two cases and review of literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Hepatosplenic and subcutaneous panniculitis-like gamma/delta T cell lymphomas are derived from different Vdelta subsets of gamma/delta T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Hepatosplenic gamma-delta T-cell lymphoma as a late-onset posttransplant lymphoproliferative disorder in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Hepato-splenic gammadelta T-cell lymphoma: a rare entity mimicking the hemophagocytic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

T gamma/delta hepatosplenic lymphoma in a heart transplant patient after an Epstein-Barr virus positive lymphoproliferative disorder: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Hepatosplenic gamma/delta T-cell lymphoma: a report of two cases in immunocompromised patients, associated with isochromosome 7q.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Splenic involvement by peripheral T-cell and NK-cell neoplasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Hepatosplenic gammadelta T-cell lymphoma: ultrastructural, immunophenotypic, and functional evidence for cytotoxic T lymphocyte differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Clinical and hematological characteristics of hepatosplenic T gamma/delta lymphoma with isochromosome for long arm of chromosome 7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Aggressive primary hepatic lymphoma in Chinese patients. Presentation, pathologic features, and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Gamma/delta T-cell posttransplantation lymphoproliferative disorder primarily in the spleen

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

In situ localization of Epstein-Barr virus encoded RNA in non-nasal/nasopharyngeal CD56-positive and CD56-negative T-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Malignant lymphomas in autoimmunity and inflammation: a review of risks, risk factors, and lymphoma characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Malignant lymphoma imitating hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Evidence for extrathymic changes in the T cell receptor gamma/delta repertoire

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Incidence of neoplasms in patients who develop sustained leukopenia during or after treatment with 6-mercaptopurine for inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Infliximab for induction and maintenance therapy for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Cellular and molecular mechanisms of the epithelial repair in IBD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale?

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Guidelines for the management of inflammatory bowel disease in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Pediatric inflammatory bowel diseases and the risk of lymphoma: should we revise our treatment strategies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twe

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolon

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Clinicopathological features of eight Korean cases of primary hepatic lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Peripheral T-cell lymphomas: Initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

Infliximab, azathioprine, or combination therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.CROHNS.2010.05.006

10.1016/J.CROHNS.2010.05.006

21 January 2018

Identifiers

DOI

1 reference

23 August 2017

1 reference

PubMed ID

21122554